Orexo has developed from being an R&D stage company to becoming a profitable fully integrated specialty pharmaceutical company with its own commercial business in the US. From a strong operational and financial platform, Orexo is aiming to become a leader in the field of addiction treatment. To achieve this, the commercial business will be broadened through business development, M&A and launch of ­proprietary pharmaceuticals and digital therapies.

Objectives and strategies 2020 and onwards

1. Broadening the portfolio of commercial products to be promoted by our US pharma and Digital Therapeutic businesses

2. Maintaining ZUBSOLV® profit contribution and ensure it is sustainable and growing over time

3. Establishing a new revenue generating business area within Digital Therapeutics and have three revenue generating products in the market in 2021

4. Launching OX124, an overdose rescue medication, in 2023 in the US